Search | IOVS | ARVO Journals

Showing 1 – 16 of 16

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

Telemedicine March 2024

Inequalities in Uptake and Use of Digital Applications for Home-Monitoring of Neovascular Age-Related Macular Degeneration in an Elderly Visually Impaired Population: The MONARCH Study

PDF

Ruth E. Hogg; Robin Wickens; Sean O'Connor; Eleanor Gidman; Elizabeth Ward; Tunde Peto; Benjamen J. L. Burton; Paul Knox; Andrew J. Lotery; Sobha Sivaprasad; Michael Donnelly; Chris A. Rogers; Barnaby C. Reeves
TAGS: exudative age-related macular degeneration, older adult, technology, follow-up
Trans. Vis. Sci. Tech.. 2024; 13(3):2. https://doi.org/10.1167/tvst.13.3.2

ARVO Annual Meeting Abstract June 2020

Implementing digital applications for self-monitoring of visual function in the MONARCH study: technological and practical challenges.

Ruth E Hogg; Robin Wickens; Charlene Treanor; Abby O'Connell; Lucy Culliford; Chris Rogers; Eleanor Gidman; Tunde Peto; Paul C Knox; Ben Burton; Andrew J Lotery; Sobha Sivaprasad; Michael Donnelly; Barney Reeves

Invest. Ophthalmol. Vis. Sci.. 2020; 61(7):3079.

ARVO Annual Meeting Abstract June 2017

Assessment of Retinal Vascular Geometry (RVG) role in patients with neovascular Age Related Macular Degeneration (nAMD) participating in IVAN study.

Maged S Habib; Bashir Al Diri; Lauren Scott; Chris Rogers; Barney C Reeves; Usha Chakravarthy; David H W Steel

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):1581.

ARVO Annual Meeting Abstract June 2017

Assessing lesion activity in neovascular AMD from colour images and optical coherence tomograms

Barney C Reeves; Simon P Harding; Tunde Peto; Alyson Muldrew; Lauren Scott; Chris Rogers; Usha Chakravarthy

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):52.

ARVO Annual Meeting Abstract September 2016

A case control study using data from the Corneal Transplant Follow-up Study II (CTFS II) to determine the influence of HLA class I matching on high-risk penetrating keratoplasty 5-year survival.

John Armitage; Mark N Jones; Helen Winton; Chris Rogers; Derek Tole; Andrew D Dick

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12):1442.

Vision Sciences Society Annual Meeting Abstract September 2016

Reduced Habituation to Naturalistic Stimuli in Autism

Anne Cardinaux; Hossein Nejati; Christy Rogers; Kleovoulos Tsourides; Tapan Gandhi; Margaret Kjelgaard; Pawan Sinha

Journal of Vision. 2016; 16(12):478. https://doi.org/10.1167/16.12.478

ARVO Annual Meeting Abstract June 2015

Corneal Transplant Follow-up Study II (CTFS II) - HLA class II matching does not reduce risk of allograft rejection in high-risk penetrating keratoplasty

John Armitage; Mark Jones; Helen Winton; Chris Rogers; Derek Tole; Andrew D Dick

Invest. Ophthalmol. Vis. Sci.. 2015; 56(7 ):4358.

ARVO Annual Meeting Abstract April 2014

Gastrointestinal serious adverse events in patients treated with intraocular ranibizumab or bevacizumab for age-related choroidal neovascularisation, what do the recent trials tell us?

Lauren Scott; Usha Chakravarthy; Rachel Nash; Susan M Downes; Simon P Harding; Barney Reeves; Chris Rogers; IVAN investigators

Invest. Ophthalmol. Vis. Sci.. 2014; 55(13):1648.

ARVO Annual Meeting Abstract April 2014

Morphological features and determinants of new geographic atrophy developing in participants in the IVAN trial.

Frank Picton; Katherine A Muldrew; Barney Reeves; Chris Rogers; Simon P Harding; Usha Chakravarthy; Tunde Peto; NetworcUK

Invest. Ophthalmol. Vis. Sci.. 2014; 55(13):4977.

ARVO Annual Meeting Abstract April 2014

Visual acuity by responder status in the IVAN clinical trial

Andrew Lotery; Lauren Scott; Simon P Harding; Barney Reeves; Chris Rogers; Usha Chakravarthy; IVAN Study Investigators

Invest. Ophthalmol. Vis. Sci.. 2014; 55(13):867.

ARVO Annual Meeting Abstract April 2014

Alterations in serum vascular endothelial growth factor after intraocular administration of antiVEGF drugs, is there an association with safety outcomes?

Usha Chakravarthy; Chris Rogers; Barney Reeves; Lauren Scott; Simon P Harding; Susan M Downes; Andrew Lotery; IVAN study Group

Invest. Ophthalmol. Vis. Sci.. 2014; 55(13):871.

ARVO Annual Meeting Abstract June 2013

The Relationship between Haemorrhage and OCT Signs and the Likelihood of Neovascular AMD being Active during Follow-up: Data from the IVAN study

Simon Harding; Barnaby Reeves; Alyson Muldrew; David Parry; Chris Rogers; Jayashree Sahni; Tunde Peto; Usha Chakravarthy; IVAN Study Group

Invest. Ophthalmol. Vis. Sci.. 2013; 54(15):3660.

ARVO Annual Meeting Abstract June 2013

Cost-effectiveness of ranibizumab and bevacizumab for neovascular age-related macular degeneration: 1 year IVAN results

Chris Rogers; Helen Dakin; Sarah Wordsworth; Giselle Abangma; James Raftery; Simon Harding; Usha Chakravarthy; Andrew Lotery; Susan Downes; Barnaby Reeves; IVAN Study Investigators

Invest. Ophthalmol. Vis. Sci.. 2013; 54(15):373.

ARVO Annual Meeting Abstract June 2013

Pharmacogenetic associations in neovascular age-related macular degeneration. Results from the IVAN study

Andrew Lotery; Jane Gibson; Angela Cree; Susan Downes; Simon Harding; Chris Rogers; Barnaby Reeves; Sarah Ennis; Usha Chakravarthy

Invest. Ophthalmol. Vis. Sci.. 2013; 54(15):6185.

ARVO Annual Meeting Abstract March 2012

Corneal Transplant Follow-up Study II (CTFS II): Patient Baseline Characteristics And Influence Of Recipient Age On Risk Of Rejection

John Armitage; Helen L. Winton; Mark N. Jones; Chris A. Rogers; Jeff L. Bidwell; Derek M. Tole; Andrew D. Dick

Invest. Ophthalmol. Vis. Sci.. 2012; 53(14):2385.

ARVO Annual Meeting Abstract April 2011

Fluctuating Levels Of Circulating VEGF In A Subset Of Patients As Part Of The Multicentre IVAN Study

Josephine V. Glenn; Shrobona Bhattycharya; Barnaby C. Reeves; Cyril McMaster; Chris A. Rogers; Alan W. Stitt; Usha Chakravarthy

Invest. Ophthalmol. Vis. Sci.. 2011; 52(14):5930.

NARROW

Content Type

Journal

Article Type

Topics

Tags

Specify Date Range

Inequalities in Uptake and Use of Digital Applications for Home-Monitoring of Neovascular Age-Related Macular Degeneration in an Elderly Visually Impaired Population: The MONARCH Study

Implementing digital applications for self-monitoring of visual function in the MONARCH study: technological and practical challenges.

Assessment of Retinal Vascular Geometry (RVG) role in patients with neovascular Age Related Macular Degeneration (nAMD) participating in IVAN study.

Assessing lesion activity in neovascular AMD from colour images and optical coherence tomograms

A case control study using data from the Corneal Transplant Follow-up Study II (CTFS II) to determine the influence of HLA class I matching on high-risk penetrating keratoplasty 5-year survival.

Reduced Habituation to Naturalistic Stimuli in Autism

Corneal Transplant Follow-up Study II (CTFS II) - HLA class II matching does not reduce risk of allograft rejection in high-risk penetrating keratoplasty

Gastrointestinal serious adverse events in patients treated with intraocular ranibizumab or bevacizumab for age-related choroidal neovascularisation, what do the recent trials tell us?

Morphological features and determinants of new geographic atrophy developing in participants in the IVAN trial.

Visual acuity by responder status in the IVAN clinical trial

Alterations in serum vascular endothelial growth factor after intraocular administration of antiVEGF drugs, is there an association with safety outcomes?

The Relationship between Haemorrhage and OCT Signs and the Likelihood of Neovascular AMD being Active during Follow-up: Data from the IVAN study

Cost-effectiveness of ranibizumab and bevacizumab for neovascular age-related macular degeneration: 1 year IVAN results

Pharmacogenetic associations in neovascular age-related macular degeneration. Results from the IVAN study

Corneal Transplant Follow-up Study II (CTFS II): Patient Baseline Characteristics And Influence Of Recipient Age On Risk Of Rejection

Fluctuating Levels Of Circulating VEGF In A Subset Of Patients As Part Of The Multicentre IVAN Study

To View More...

You must be signed into an individual account to use this feature.